News

As part of the deal, Nuo will receive an upfront payment from Rohto in return for an exclusive license and the right to develop and commercialize Aurix in

Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE compound. It has also secured orphan designation in multiple myeloma from the European Medicines Agency (EMA).

Savaysa is an oral, once-daily selective factor Xa-inhibitor developed to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). Daiichi Sankyo

The antibiotic compound has been discovered in a screen against NovoBiotic’s extract library generated from previously uncultured microbes. NovoBiotic president Dr Dallas Hughes said: "The discovery of teixobactin

The trial, which is designed to evaluate the efficacy, safety and pharmacokinetics of mocetinostat, will enroll patients whose tumors have mutations or deletions of the CREBBP and/or EP300

Under the deal, Tetragenetics will use its ion channel production technology, SionX, to produce about five ion channel antigens for MedImmune’s antibody drug discovery programs. The company said

The Committee also recommended approval of the biosimilar for use in all indications included in the reference product’s (Amgen’s NEUPOGEN) label. Highlights Oncologic Drugs Advisory Committee (ODAC) votes

The effort will combine the unprecedented genomic and clinical data from the MMRF’s landmark CoMMpass Study with revolutionary GNS machine learning platforms and rapid computer simulations. The work

In 2013, Ferrer successfully completed a first phase III clinical trial of Ozenoxacin in adult and paediatric patients aged two years and older with impetigo. The study demonstrated